Bioeq’s Ranivisio ranibizumab biosimilar has gained European Commission authorization for all innovator indications including wet AMD, the leading cause of blindness among over-65s.

Formycon has reported positive preliminary efficacy and safety data from the Phase III program for its FYB202 proposed ustekinumab biosimilar rival to Stelara.

Citing low risk of a clinically impactful immunogenic response from systemic anti-drug antibodies and intraocular inflammation when alternating between Coherus’ Cimerli and Genentech’s reference product ranibizumab, US FDA says a switching study would not be informative.

Citing low risk of a clinically impactful immunogenic response from systemic anti-drug antibodies and intraocular inflammation when alternating between Coherus’ Cimerli and Genentech’s reference product ranibizumab, US FDA says a switching study would not be informative.